Metformin has no impact on nitric oxide production in patients with pre-diabetes - 17/06/21
, Paulina Fortuna b , Bernadetta Kałuża c , Karolina Sutkowska d , Jerzy Wiśniewski e , Andrzej Gamian Prof f Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Aims/Introduction |
The authors evaluated the impact of different dose of metformin on NO (nitric oxide) production in subjects with pre-diabetes.
Materials and Methods |
The metformin-naïve patients from one Diabetic Center with newly diagnosed pre-diabetes, without cardio-vascular diseases, were randomized (based on the identification number, individual for each inhabitant in the country) for treatment with different doses of metformin (group A 3 × 500 mg, group B 3 × 1000 mg) for 12 weeks. Then, the subjects from group B were switched to dose 3 × 500 for the last 3 weeks. The wide panel of L-arginine/NO pathway metabolites concentrations was assessed using the liquid chromatography-mass spectrometry technique.
Results |
Between October 2017 and December 2018, 36 individuals were initially randomized to intervention groups. The study was completed with 25 subjects: 14 patients in group A, 11 in group B; also 11 healthy volunteers were recruited. There was no difference between participants with pre-diabetes and healthy volunteers as regards the baseline characteristics except for fasting glucose and fatty liver. The decrease of L-citrulline concentration only was reported for treatment groups during the intervention period, with no change for the other NO-production related substances.
Conclusion |
It was the first study on the in vivo release of NO in humans with different metformin doses in patients with pre-diabetes. Metformin did not seem to increase NO production measured by the citrulline plasma levels, irrespective of the dose. The citrulline concentration change might indicate the drug impact on the condition of the enterocytes.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | The metformin has no impact on NO production. |
• | Even the highest accepted dose of metformin does not change the results. |
• | This observation on humans supports the previous ones conducted on mice. |
• | The change in citrulline level was observed while metformin was taken. |
Keywords : Metformin, NO-nitric oxide, Pre-diabetic state
Plan
Vol 140
Article 111773- août 2021 Retour au numéro
Article précédent
- The active ingredients and mechanisms of Longchai Jiangxue Formula in treating PV, based on UPLC/Q-TOF-MS/MS, systematic pharmacology, and molecular biology validation
- Jing Ming, Weiyi Liu, Hongwei Wu, Yujin Li, Erpeng Yang, Ziqing Wang, Haiyan Xiao, Richeng Quan, Xiaomei Hu
- The enzyme L-isoaspartyl (D-aspartyl) methyltransferase promotes migration and invasion in human U-87 MG and U-251 MG glioblastoma cell lines
- Fatima Belkourchia, Richard R. Desrosiers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?